LDS/Medical Tests/Cytochrome P450 4F2 (CYP4F2) Genotyping

Cytochrome P450 4F2 (CYP4F2) Genotyping

The CYP4F2 gene is located at 19p13.2 and codes for member 2 of subfamily F of the superfamily of cytochrome P450 enzymes. The enzymes are monooxygenases in the endoplasmic reticulum that are important in the metabolism of xenobiotics, drugs, as well as steroidogenesis, cholesterol, and lipid synthesis. The enzyme also has a key role in the negative regulation of vitamin K which is required for the post-translational activation of coagulation factors by gamma-carboxylation. Variants in the CYP4F2 gene are associated with decreased removal of excess vitamin K.

The Genome-Wide Association Studies (GWAS) identified the T allele of rs2108622 which is responsible for excess vitamin k inactivation. Carriers of the T allele at rs2108622 are predicted to have decreased CYP4F2 protein levels resulting in reduced vitamin K metabolism and greater vitamin K availability. Non-carriers of the T allele are predicted to have normal CYP4F2 protein levels and normal vitamin K metabolism. Patients with this variant generally require 5-10% higher doses for the desired response INR response. It is postulated that this is due to higher-than-normal levels of activated vitamin K in cells. However, variants in another genes, such as VKORC1 and CYP2C9 are much more common causes of warfarin resistance than this CYP4F2 variant.

This test is usually ordered as a part of the pharmacogenetic panel in conjunction with VKORC1 and CYP2C9 for predicting warfarin resistance and dosing.

  • In conjunction with VKORC1 and CYP2C9 useful in predicting warfarin resistance
  • In conjunction with VKORC1 and CYP2C9 useful in personalized warfarin dosing
A positive result indicates the presence of the rs2108622 T allele and implies mild warfarin resistance. [Patients with a positive test require 5-10% higher doses of warfarin than that calculated using INR] A negative result indicates the absence of the rs2108622 T allele but doesn’t necessarily rule out warfarin resistance since there are other variant genes like in VKORC1 and CYP2C9. Drug response also largely depends upon the metabolizing ability of the patient’s liver.

CYP4F2 rs2108622 C/C (Normal activity)

Allele Specific Primer Extension (ARMS) by Real-time Polymerase chain reaction (PCR), Next generation sequencing (NGS), Conventional Sequencing.

Whole Blood EDTA (Lavender) or ACD (yellow) or Heparin (Green) top tube, buccal swab, saliva.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: 1 month
VKORC1 variant testing, CYP4502C9, CBC, PT/INR, aPTT, fibrinogen assay, FV Leiden, vWF.
3-5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login